Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention of Symptomatic Skeletal Events with Denosumab Every 4 Weeks versus Every 12 Weeks
2014-001189-87Phase 3Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of denosumab in prostate cancer (PCa), breast cancer and bone metastases (2 arms), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Time to first on-trial symptomatic skeletal event. Started Apr 2017; status: completed.
02
Drugs
denosumab
03
Conditions
prostate cancer (PCa)breast cancerbone metastases
Beyond the preview
Go deeper on 2014-001189-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001189-87.